Heron Therapeuti (HRTX) - Total Liabilities
Based on the latest financial reports, Heron Therapeuti (HRTX) has total liabilities worth $237.08 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Heron Therapeuti liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Heron Therapeuti - Total Liabilities Trend (1987–2025)
This chart illustrates how Heron Therapeuti's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Heron Therapeuti asset portfolio.
Heron Therapeuti Competitors by Total Liabilities
The table below lists competitors of Heron Therapeuti ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gemfields Group Ltd
JSE:GML
|
South Africa | ZAC206.14 Million |
|
Mastermyne Group Ltd
AU:MYE
|
Australia | AU$37.93 Million |
|
Mesa Air Group Inc
NASDAQ:MESA
|
USA | $211.57 Million |
|
Suprema ID Inc
KQ:317770
|
Korea | ₩31.52 Billion |
|
AmFIRST Real Estate Investment Trust
KLSE:5120
|
Malaysia | RM838.17 Million |
|
MCE Holdings Bhd
KLSE:7004
|
Malaysia | RM71.16 Million |
|
Kedoya Adyaraya Tbk PT
JK:RSGK
|
Indonesia | Rp253.79 Billion |
|
Wp Energy Public Company Limited
BK:WP
|
Thailand | ฿5.52 Billion |
Liability Composition Analysis (1987–2025)
This chart breaks down Heron Therapeuti's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See HRTX equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 25.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Heron Therapeuti's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Heron Therapeuti (1987–2025)
The table below shows the annual total liabilities of Heron Therapeuti from 1987 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $241.54 Million | -9.47% |
| 2024-12-31 | $266.80 Million | +4.02% |
| 2023-12-31 | $256.48 Million | +8.05% |
| 2022-12-31 | $237.38 Million | +4.05% |
| 2021-12-31 | $228.14 Million | +94.88% |
| 2020-12-31 | $117.06 Million | +7.45% |
| 2019-12-31 | $108.95 Million | +18.40% |
| 2018-12-31 | $92.02 Million | -10.81% |
| 2017-12-31 | $103.17 Million | +16.27% |
| 2016-12-31 | $88.73 Million | +349.62% |
| 2015-12-31 | $19.73 Million | +44.90% |
| 2014-12-31 | $13.62 Million | +94.79% |
| 2013-12-31 | $6.99 Million | +68.32% |
| 2012-12-31 | $4.15 Million | +12.48% |
| 2011-12-31 | $3.69 Million | +131.54% |
| 2010-12-31 | $1.59 Million | -25.99% |
| 2009-12-31 | $2.15 Million | -48.71% |
| 2008-12-31 | $4.20 Million | -43.79% |
| 2007-12-31 | $7.48 Million | +43.99% |
| 2006-12-31 | $5.19 Million | +87.71% |
| 2005-12-31 | $2.77 Million | -3.29% |
| 2004-12-31 | $2.86 Million | +51.16% |
| 2003-12-31 | $1.89 Million | -19.15% |
| 2002-12-31 | $2.34 Million | -46.02% |
| 2001-12-31 | $4.33 Million | -25.74% |
| 2000-12-31 | $5.84 Million | -49.24% |
| 1999-12-31 | $11.50 Million | +33.72% |
| 1998-12-31 | $8.60 Million | -38.57% |
| 1997-12-31 | $14.00 Million | +4.48% |
| 1996-12-31 | $13.40 Million | -25.14% |
| 1995-12-31 | $17.90 Million | +52.99% |
| 1994-12-31 | $11.70 Million | -15.83% |
| 1993-12-31 | $13.90 Million | +71.60% |
| 1992-12-31 | $8.10 Million | +26.56% |
| 1991-12-31 | $6.40 Million | +20.75% |
| 1990-12-31 | $5.30 Million | +43.24% |
| 1989-12-31 | $3.70 Million | +5.71% |
| 1988-12-31 | $3.50 Million | -7.89% |
| 1987-12-31 | $3.80 Million | -- |
About Heron Therapeuti
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It … Read more